Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $37.6mm for Provention Bio

Executive Summary

Provention Bio Inc. netted $37.6mm through a public offering of 5mm common shares at $8. The company is developing therapeutics for immune-mediated diseases and will use the proceeds to continue work on its pipeline projects for conditions including diabetes, inflammatory bowel disease, celiac disease, lupus, and acute coxsackie B virus. Concurrent with the public stock sale, Provention also announced that it received a $20mm private equity investment from strategic partner Amgen.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies